Journal
GASTROENTEROLOGY
Volume 148, Issue 7, Pages 1294-1310Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2015.02.056
Keywords
WNT; beta-Catenin; E-Cadherin; Liver Fibrosis; NASH; HCC; Liver Tumors
Categories
Funding
- National Institutes of Health [1R01DK62277, 1R01DK100287, 1R01DK095498]
- Endowed Chair for Experimental Pathology
Ask authors/readers for more resources
beta-catenin (encoded by CTNNB1) is a subunit of the cell surface cadherin protein complex that acts as an intracellular signal transducer in the WNT signaling pathway; alterations in its activity have been associated with the development of hepatocellular carcinoma and other liver diseases. Other than WNT, additional signaling pathways also can converge at beta-catenin. beta-catenin also interacts with transcription factors such as T-cell factor, forkhead box protein O, and hypoxia inducible factor 1 alpha to regulate the expression of target genes. We discuss the role of beta-catenin in metabolic zonation of the adult liver. beta-catenin also regulates the expression of genes that control metabolism of glucose, nutrients, and xenobiotics; alterations in its activity may contribute to the pathogenesis of nonalcoholic steatohepatitis. Alterations in beta-catenin signaling may lead to activation of hepatic stellate cells, which is required for fibrosis. Many hepatic tumors such as hepatocellular adenomas, hepatocellular cancers, and hepatoblastomas have mutations in CTNNB1 that result in constitutive activation of beta-catenin, so this molecule could be a therapeutic target. We discuss how alterations in beta-catenin activity contribute to liver disease and how these might be used in diagnosis and prognosis, as well as in the development of therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available